drugset / Trial / NCT05629598

A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

NCT05629598

Phase 2 Unknown 150 enrolled Angde Biotech Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia. Patients with renal anemia on regular dialysis treatment are expected to be enrolled in this study.

Timeline

Start
2022-04-13
Primary completion
2023-03-17
Completion
2023-08-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator Human erythropoietin Protein / enzyme biologic
Subject PEG-EPO Protein / enzyme biologic

Indications